Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | CASR | P41180 | 1/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24011651 | 0.85 | MEN1 (0.54) | SMN1; SMN2ALDH1A1NPC1RAB9AITGB3 | |
| SCHEMBL26633714 | 0.83 | NAMPT (0.48) | SMN1; SMN2ALDH1A1ITGB3ITGA2BNAMPT | |
| SCHEMBL26633836 | 0.82 | NAMPT (0.50) | ALDH1A1NAMPT | |
| SCHEMBL26633796 | 0.79 | SMN1; SMN2 (0.44) | SMN1; SMN2ALDH1A1NPC1RAB9ACASR | |
| SCHEMBL24011184 | 0.79 | NAMPT (0.57) | CASRNAMPT | |
| SCHEMBL24011366 | 0.78 | SMN1; SMN2 (0.76) | SMN1; SMN2ALDH1A1NPC1RAB9APOLB | |
| SCHEMBL26633900 | 0.78 | NAMPT (0.46) | NAMPT | |
| SCHEMBL24011100 | 0.77 | CYP2C9 (0.49) | SMN1; SMN2NPC1CASRNAMPT | |
| SCHEMBL29207994 | 0.77 | ALDH1A1 (0.62) | SMN1; SMN2ALDH1A1NPC1RAB9AKMT2A | |
| SCHEMBL24011409 | 0.76 | CASR (0.59) | SMN1; SMN2ALDH1A1NPC1RAB9ACASR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348369-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348369-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348369-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348369-A1 | NAMPT MODULATORS | NAMPT, NNT, NAPRT | SMN1; SMN2 610/4885ALDH1A1 982/4885NPC1 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.